Mannkind Corporation - Company & Market Research Reports

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

From
From
From
From
From
From
From
Type 2 Diabetes - Pipeline Review, H1 2018 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1109 Pages
From
From
From
Type 2 Diabetes - Pipeline Review, H2 2017 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H2 2017

  • Drug Pipelines
  • 1126 Pages
From
From
From
From
From
Loading Indicator
adroll